

Integrated Impact Assessment Report for Clinical Commissioning Policies			
Policy Reference Number	1750		
Policy Title	Vertebral Body Tethering for Scoliosis Proposal not for routine commission (ref A3.1)		
Lead Commissioner	David Stockdale	Clinical Lead	Vinay Jasani
Finance Lead	Click here to enter text.	Analytical Lead	Click here to enter text.

Integrated Impact Assessment - Index				
Section A - Activity	Section B - Service	Section C - Finance		
A1 Current Patient Population & Demography/ Growth	B1 Service Organisation	C1 Tariff		
A2 Future Patient Population & Demography	B2 Geography & Access	C2 Average Cost per Patient		
A3 Activity	B3 Implementation	C3 Overall Cost Impact of this Policy to NHS England		
A4 Existing Patient Pathway	B4 Collaborative Commissioning	C4 Overall cost impact of this policy to the NHS as a whole		
A5 Comparator (next best alternative treatment) Patient Pathway		C5 Funding		
A6 New Patient Pathway		C6 Financial Risks Associated with Implementing this Policy		
A7 Treatment Setting		C7 Value for Money		
A8 Coding		C8 Cost Profile		
A9 Monitoring				

About this Impact Assessment: instructions for completion and explanatory notes

- Each section is divided into themes.
- Each theme sets out a number of questions.
- All questions are answered by selecting a drop down option or including free text.
- Free text boxes are provided to enable succinct relevant commentary to be added which explains the rationale for response or assumption. Please limit responses to 3 sentences of explanatory text.
- Data in this document is either drawn from one of the relevant policy documents or a source for the information is provided.
- Where assumptions are included where data is not available, this is specified.

Section A - Activity Impact			
A1 Current Patient Population & Demography / Growth			
A1.1 Prevalence of the disease/condition.	Additional 80 patients per Source: Policy Proposition	-	3
A1.2 Number of patients currently eligible for the treatment according to the proposed policy commissioning criteria.	N/A - do not routinely constrained Source: required Please specify Click here to enter text.	ommission	
A1.3 Age group for which the treatment is proposed according to the policy commissioning criteria.	All ages Please specify Click here to enter text.		
A1.4 Age distribution of the patient population eligible according to the proposed policy commissioning criteria	enter number. if relevant Source: required Please specify Click here to enter text.		
A1.5 How is the population currently distributed geographically?	Evenly If unevenly, estimate reg North Midlands & East London South	enter % enter % enter % enter % enter %	ution by %:

	Source: Policy Proposition section 6 Please specify Click here to enter text.		
A2 Future Patient Population & Demography			
A2.1 Projected changes in the disease/condition epidemiology, such as incidence or prevalence (prior to applying the new policy) in 2, 5, and 10 years?	Constant If other, Click here to enter text. Source: Policy Proposition section 6		
A2.2 Are there likely to be changes in demography of the patient population and would this impact on activity/outcomes?	No Please specify Click here to enter text. Source: Policy Proposition section 6/other		
A2.3 Expected net increase or decrease in the number of patients	YR2 +/-	enter number.	
who will be eligible for the service, according to the proposed service specification commissioning criteria, per year in years 2-5	YR3 +/-	enter number.	
and 10?	YR4 +/-	enter number.	
	YR5 +/-	enter number.	
	YR10 +/-	enter number.	
	Source: Service	e specification propo	sition section 3.1
Are these numbers in line with ONS growth assumptions for the age specific population? If not please justify the growth assumptions made.	Choose an item Click here to en		

A3 Activity	
A3.1 What is the purpose of new policy?	Confirm non-routine commissioning position of an additional new treatment Please specify Click here to enter text.
A3.2 What is the annual activity associated with the existing pathway for the eligible population?	80 Source: Please specify Policy proposition – based on British Spine Registry data
A3.3 What is the estimated annual activity associated with the proposed policy proposition pathway for the eligible population?	0 Source: required Please specify Do not routinely commission
A3.4 What is the estimated annual activity associated with the next best alternative comparator pathway for the eligible population? If the only alternative is the existing pathway, please state 'not applicable' and move to A4.	80 Source: required Please specify See A3.2
A4 Existing Patient Pathway	
A4.1 Existing pathway: Describe the relevant currently routinely commissioned:	Existing treatment options include magnetic lengthened rods or surgically lengthened rods

 Treatment or intervention Patient pathway Eligibility and/or uptake estimates. 	Source: NHS England policy
A4.2. What are the current treatment access and stopping criteria?	NA Source: Policy Proposition
A4.3 What percentage of the total eligible population is expected to: a) Be clinically assessed for treatment b) Be considered to meet an exclusion criteria following assessment c) Choose to initiate treatment d) Comply with treatment e) Complete treatment? A5 Comparator (next best alternative treatment) Patient Pathway	
(NB: comparator/next best alternative does not refer to current pathway but to an a	птетнапуе орноп)
A5.1 Next best comparator: Is there another 'next best' alternative treatment which is a relevant comparator? If yes, describe relevant Treatment or intervention Patient pathway Actual or estimated eligibility and uptake	Yes If yes, Existing treatment options include magnetic lengthened rods or surgically lengthened rods Source: NHS England policy
A5.2 What percentage of the total eligible population is estimated to:	Total estimated eligible Not known

 a) Be clinically assessed for treatment b) Be considered to meet an exclusion criteria following assessment c) Choose to initiate treatment d) Comply with treatment e) Complete treatment? 	a) enter % b) enter % c) enter % d) enter % e) enter % Source: required
A6 New Patient Pathway	
A6.1 What percentage of the total eligible population is expected to:	If not known, please specify N/A
a) Be clinically assessed for treatment	a) enter %
b) Be considered to meet an exclusion criteria following assessment	b) enter %
c) Choose to initiate treatment	c) enter %
d) Comply with treatment	d) enter %
e) Complete treatment?	e) enter %
	Source: Do not routinely commission proposal
A6.2 Specify the nature and duration of the proposed new treatment	Choose an item.
or intervention.	For time limited treatments, specify frequency and/or duration.
	Click here to enter text.
	Source: Do not routinely commission proposal
A7 Treatment Setting	
A7.1 How is this treatment delivered to the patient?	Select all that apply: N/A

	Emergency/Urgent care att	endance	
	Acute Trust: inpatient		
	Acute Trust: day patient		
	Acute Trust: outpatient		
	Mental Health provider: inp	atient	
	Mental Health provider: out	patient	
	Community setting		
	Homecare		
	Other		
	Please specify: Click here to enter text.		
A7.2 What is the current number of contracted providers for the	NORTH	number	
eligible population by region?	MIDLANDS & EAST	number	
	LONDON	number	
	SOUTH	number	
A7.3 Does the proposition require a change of delivery setting or capacity requirements?	No Please specify: Do not routinely commission Source: Policy proposition		

A8 Coding				
A8.1 Specify the datasets used to record the new patient pathway	Select all that apply: N/A			
activity.	Aggregate Contract Monitoring *			
*expected to be populated for all commissioned activity	Patient level contract monitoring			
	Patient level drugs dataset			
	Patient level devices dataset			
	Devices supply chain reconciliation dataset			
	Secondary Usage Service (SUS+)			
	Mental Health Services DataSet (MHSDS)			
	National Return**			
	Clinical Database**			
	Other**			
	**If National Return, Clinical database or other selected, please specify: Click here to enter text.			
A8.2 Specify how the activity related to the new patient pathway will	Select all that apply: N/A			
be identified.	OPCS v4.8			
	ICD10			
	Treatment function code			
	Main Speciality code			
	HRG			
	SNOMED			

	Clinical coding / terming methodology used by clinical profession
A8.3 Identification Rules for Drugs:	Not applicable
How are drug costs captured?	If the drug has already been specified in the current NHS England Drug List please specify drug name and drug indication:
	Click here to enter text.
	If the drug has NOT already been specified in the current NHS England Drug List please give details of action required and confirm that this has been discussed with the pharmacy lead:
	Click here to enter text.
A8.4 Identification Rules for Devices:	Not applicable
How are device costs captured?	If the device is covered by an existing category of HCTED please specify the Device Category (as per the National Tariff Payment System Guidance).
	Click here to enter text.
	If the device is not excluded from Tariff nor covered within existing National or Local prices please specify details of action required and confirm that this has been discussed with the HCTED team.
	Click here to enter text.
A8.5 Identification Rules for Activity:	Not captured by an existing specialised service line
How are activity costs captured?	If activity costs are already captured please specify the specialised service code and description (e.g. NCBPS01C Chemotherapy).
	Click here to enter text.
	If activity costs are already captured please specify whether this service needs a separate code. Choose an item.
	If the activity is captured but the service line needs amendment please specify whether the proposed amendments have been documented and

	agreed with the Identification Rules team. Click here to enter text. If the activity is not captured please specify whether the proposed identification rules have been documented and agreed with the Identification Rules team.	
A9 Monitoring		
A9.1 Contracts Specify any new or revised data flow or data collection requirements, needed for inclusion in the NHS Standard Contract Information Schedule.	None Please specify Do not routinely commision	
A9.2 Excluded Drugs and Devices (not covered by the Zero Cost Model) For treatments which are tariff excluded drugs or devices not covered by the Zero Cost Model, specify the pharmacy or device monitoring required, for example reporting or use of prior approval systems.	Select all that apply: Drugs or Device MDS Blueteq Other prior approval Please specify: N?A	
A9.3 Business intelligence Is there potential for duplicate reporting?	No If yes, please specify mitigation: Click here to enter text.	
A9.4 Contract monitoring Is this part of routine contract monitoring?	No If yes, please specify contract monitoring requirement: Click here to enter text.	

A9.5 Dashboard reporting Specify whether a dashboard exists for the proposed intervention?	No If yes, specify how routine performance monitoring data will be used for dashboard reporting. Click here to enter text.
	If no, will one be developed?
	No – do not routinely commission
A9.6 NICE reporting Are there any directly applicable NICE or equivalent quality standards which need to be monitored in association with the new policy?	No If yes, specify how performance monitoring data will be used for this purpose. Click here to enter text.
Section B	- Service Impact
B1 Service Organisation	
B1.1 Describe how the service is currently organised? (i.e. tertiary centres, networked provision etc.)	Scoliosis centres are tertiary centres Source: Policy proposition
B1.2 Will the proposition change the way the commissioned service is organised?	No Please specify: Click here to enter text. Source: required
B1.3 Will the proposition require a new approach to the organisation of care?	No change to delivery of care Please specify: Click here to enter text.

32.1 Where do current referrals come from?	Select all that apply:	
	GP	
	Secondary care	
	Tertiary care	\boxtimes
	Other	
	Please specify: Click here to enter text.	
32.2 What impact will the new policy have on the sources of eferral?	No impact Please specify: Do not routinely commis	ssion
32.3 Is the new policy likely to improve equity of access?	No impact Please specify: Do not routinely commis Source: Equalities Impa	
32.4 Is the new policy likely to improve equality of access and/or outcomes?	No impact Please specify: Do not routinely commis Source: Equalities Impa	

B3 Implementation	
B3.1 Will commissioning or provider action be required before implementation of the proposition can occur?	No action required Please specify: Do not routinely commission
B3.2 Time to implementation: Is a lead-in time required prior to implementation?	No - go to B3.4 If yes, specify the likely time to implementation: Enter text
B3.3 Time to implementation: If lead-in time is required prior to implementation, will an interim plan for implementation be required?	Choose an item. If yes, outline the plan: Click here to enter text.
B3.4 ls a change in provider physical infrastructure required?	No Please specify: Do not routinely commission
B3.5 Is a change in provider staffing required?	No Please specify: Click here to enter text.
B3.6 Are there new clinical dependency and/or adjacency requirements that would need to be in place?	No Please specify: Click here to enter text.
B3.7 Are there changes in the support services that need to be in place?	No Please specify: Click here to enter text.

B3.8 Is there a change in provider and/or inter-provider governance required? (e.g. ODN arrangements / prime contractor)	No Please specif Click here to	=			
B3.9 Is there likely to be either an increase or decrease in the number of commissioned providers? If yes, specify the current and estimated number of providers required in each region	No change Please complete table:				
	Region	Current no. of providers	Future State expected range	Provisional or confirmed	
	North			select	
	Midlands & East			select	
	London			select	
	South			select	
	Total			select	
	Please specific Click here to	•			
B3.10 Specify how revised provision will be secured by NHS	Select all tha	at apply: N/A			
England as the responsible commissioner.	Publication and notification of new policy				
	Market intervention required				
	Competitive selection process to secure increase or decrease provider configuration			or 🗆	
	Price-based selection process to maximise cost effectiveness				
	Any qualified	l provider			

	National C	Commercial Agreements e.g. drugs, devices		
		Procurement		
	Other		\boxtimes	
	Please spe	cify:		
	Click here	to enter text.		
B4 Place-based Commissioning				
B4.1 Is this service currently subject to, or planned for, place-based commissioning arrangements? (e.g. future CCG lead, devolved commissioning arrangements, STPs)	No Please specify: Click here to enter text.			
Section C	- Finance Impact			
C1 Tariff/Pricing				
C1.1 How is the service contracted and/or charged?	Select all	that apply: N/A		
Only specify for the relevant section of the patient pathway		Not separately charged – part of local or nation	onal tariffs	
	Drugs	Excluded from tariff – pass through		
		Excluded from tariff - other		
	Devices	Not separately charged – part of local or nation	onal tariffs	
		Evaluated from toriff (evaluation 7014)	Alama arla	
	Devices	Excluded from tariff (excluding ZCM) - pass	tnrougn	
	Devices	Excluded from tariff (excluding ZCM) – pass (Excluded from tariff (excluding ZCM) – other	tnrougn	

		Via Zero Cost Model	
		Paid entirely by National Tariffs	
		Paid entirely by Local Tariffs	
		Partially paid by National Tariffs	
	Activity	Partially paid by Local Tariffs	
		Part/fully paid under a Block arrangement	
		Part/fully paid under Pass-Through arrangements	
		Part/fully paid under Other arrangements	
Where not included in national or local tariffs, list each drug or combination, dosage, quantity, list price including VAT if applicable and any other key information e.g. Chemotherapy Regime. NB discounted prices or local prices must not be included as these are subject to commercial confidentiality and must not be disclosed.			
C1.3 Device Costs Where not included in national or local tariff, list each element of the excluded device, quantity, list or expected price including VAT if applicable and any other key information. NB: Discounted prices or local prices must not be included as these are subject to commercial confidentiality and must not be disclosed.	N/A		
C1.4 Activity Costs covered by National Tariffs List all the HRG codes, HRG descriptions, national tariffs (excluding MFF), volume and other key costs (e.g. specialist top up %)	N/A		

N/A		
No Please spec	ify: Click here to enter text.	
YR1	enter number.	
YR2	enter number.	
YR3	enter number.	
YR4	enter number.	
YR5	enter number.	
	•	
	No Please spec YR1 YR2 YR3 YR4 YR5 If yes, please	No Please specify: Click here to enter text. YR1 enter number. YR2 enter number. YR3 enter number. YR4 enter number.

C3.1 Specify the budget impact of the proposal on NHS England in relation to the relevant pathway.	Cost neutral Please specify: Do not routinely commission
C3.2 If the budget impact on NHS England cannot be identified set out the reasons why this cannot be measured.	N/A
C3.3 If the activity is subject to a change of commissioning responsibility, from CCG to NHS England, has a methodology for the transfer of funds been identified, and calculated?	N/A
C4 Overall cost impact of this policy to the NHS as a whole	
C4.1 Specify the budget impact of the proposal on other parts of the NHS.	Budget impact for CCGs: Cost neutral Budget impact for providers: Cost neutral Please specify: Do not routinely commission
C4.2 Taking into account responses to C3.1 and C4.1, specify the budget impact to the NHS as a whole.	Cost neutral Please specify: Do not routinely commission
C4.3 Where the budget impact is unknown set out the reasons why this cannot be measured	N/A

C4.4 Are there likely to be any costs or savings for non-NHS commissioners and/or public sector funders?	No Please specify: Do not routinely commission
C5 Funding	
C5.1 Where a cost pressure is indicated, state known source of funds for investment, where identified, e.g. decommissioning less clinically or cost-effective services.	N/A
C6 Financial Risks Associated with Implementing this Policy	
C6.1 What are the material financial risks to implementing this policy?	N/A
C6.2 How can these risks be mitigated?	N/A
C6.3 What scenarios (differential assumptions) have been explicitly tested to generate best case, worst case and most likely total cost scenarios?	N/A
C6.4 What scenario has been approved and why?	N/A
C7 Value for Money	

C7.1 What published evidence is available that the treatment is cost effective as evidenced in the evidence review?	There is no published evidence of cost-effectiveness Please specify: Click here to enter text.				
C7.2 Has other data been identified through the service specification development relevant to the assessment of value for money?	Select all that apply:				
	Available pricing data suggests the treatment is equivalent cost compared to current/comparator treatment				
	Available pricing data suggests the treatment is lower cost compared to current/comparator treatment				
	Available clinical practice data suggests the new treatment has the potential to improve value for money				
	Other data has been identified				
	No data has been identified	\boxtimes			
	The data supports a high level of certainty about the impact on value				
	The data does not support a high level of certainty about the impact on value				
	Please specify:				
	Click here to enter text.				
C8 Cost Profile					
C8.1 Are there non-recurrent capital or revenue costs associated with this policy?	No If yes, specify type and range: Click here to enter text.				

C8.2 If yes, confirm the source of funds to meet these costs.	Click here to enter text.